化疗联合参麦注射液对晚期非小细胞肺癌患者细胞免疫及肿瘤恶性程度的影响(4)
[3]Velcheti V，Schalper K A，Carvajal D E，et al.Programmed death ligand-1 expression in non-small cell lung cancer[J].Laboratory investigation； a journal of technical methods and pathology，2014，94(1)：107-116.
[4]Peters S，Adjei AA，Gridelli C，et al.Metastatic non-small-cell lung cancer (NSCLC)：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up[J].Ann Oncol，2012，23 Suppl 7：vii56-64.
[5]Shaw A T，Kim D W，Mehra R，et al.Ceritinib in ALK-rearranged non-small-cell lung cancer[J].New England Journal of Medicine，2014，370(13)：1189.
, 百拇医药
[6]Lynch TJ，Bell DW，Sordella R，et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med，2004，350(21)：2129-39.
[7]Schiller JH，Harrington D，Belani CP，et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med，2002，346(2)：92-98.
[8]Inoue A，Suzuki T，Fukuhara T，et al.Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations[J].J Clin Oncol，2006，24(21)：3340-3346.
, 百拇医药
[9]胡毅，冯奉仪.晚期非小细胞肺癌化疗研究现状及展望[J].国外医学：肿瘤学分册，2002，29(3)：197-201.
[10]Dimitroulis J，Stathopoulos GP.Evolution of non-small cell lung cancer chemotherapy (Review)[J].Oncol Rep，2005，13(5)：923-930.
[11]Cao Y，Li P，Tan KJ.[Clinical observation on shenmai injection in preventing and treating adverse reaction of chemotherapy on advanced non-small cell lung cancer][J].Zhongguo Zhong Xi Yi Jie He Za Zhi，2006，26(6)：550-552.
, http://www.100md.com
[12]Yang，Yuzhen，Peng，et al.Clinical observation of Shenmai injection in the treatment for adverse reactions of chemotherapy on advanced non-small cell lung cancer[J].The Chinese-German Journal of Clinical Oncology，2008，7(2)：81-83.
[13]W.Leszczyński，L.Hawrylewicz，A.Namys-Kaletka，et al.Description of non-complanar conformal radiotherapy technique used in stomach cancer patients[J].Onkologia I Radioterapia，2014，26(1)：30-35.
[14]全國肿瘤防治办公室.中国常见恶性肿瘤诊治规范[S].北京：北京医科大学，中国协和医科大学联合出版社，1990.
, 百拇医药
[15]杨学宁，吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学，2004，4(2)：85-90，111.
[16]Danesi R，Pasqualetti G，Giovannetti E，et al.Pharmacogenomics in non-small-cell lung cancer chemotherapy[J].Adv Drug Deliv Rev，2009，61(5)：408-417.
[17]Scagliotti GV，Lodico D，Gozzelino F，et al.Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide[J].Oncology，1985，42(4)：224-228., 百拇医药(罗丽华)
[4]Peters S，Adjei AA，Gridelli C，et al.Metastatic non-small-cell lung cancer (NSCLC)：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up[J].Ann Oncol，2012，23 Suppl 7：vii56-64.
[5]Shaw A T，Kim D W，Mehra R，et al.Ceritinib in ALK-rearranged non-small-cell lung cancer[J].New England Journal of Medicine，2014，370(13)：1189.
, 百拇医药
[6]Lynch TJ，Bell DW，Sordella R，et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med，2004，350(21)：2129-39.
[7]Schiller JH，Harrington D，Belani CP，et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med，2002，346(2)：92-98.
[8]Inoue A，Suzuki T，Fukuhara T，et al.Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations[J].J Clin Oncol，2006，24(21)：3340-3346.
, 百拇医药
[9]胡毅，冯奉仪.晚期非小细胞肺癌化疗研究现状及展望[J].国外医学：肿瘤学分册，2002，29(3)：197-201.
[10]Dimitroulis J，Stathopoulos GP.Evolution of non-small cell lung cancer chemotherapy (Review)[J].Oncol Rep，2005，13(5)：923-930.
[11]Cao Y，Li P，Tan KJ.[Clinical observation on shenmai injection in preventing and treating adverse reaction of chemotherapy on advanced non-small cell lung cancer][J].Zhongguo Zhong Xi Yi Jie He Za Zhi，2006，26(6)：550-552.
, http://www.100md.com
[12]Yang，Yuzhen，Peng，et al.Clinical observation of Shenmai injection in the treatment for adverse reactions of chemotherapy on advanced non-small cell lung cancer[J].The Chinese-German Journal of Clinical Oncology，2008，7(2)：81-83.
[13]W.Leszczyński，L.Hawrylewicz，A.Namys-Kaletka，et al.Description of non-complanar conformal radiotherapy technique used in stomach cancer patients[J].Onkologia I Radioterapia，2014，26(1)：30-35.
[14]全國肿瘤防治办公室.中国常见恶性肿瘤诊治规范[S].北京：北京医科大学，中国协和医科大学联合出版社，1990.
, 百拇医药
[15]杨学宁，吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学，2004，4(2)：85-90，111.
[16]Danesi R，Pasqualetti G，Giovannetti E，et al.Pharmacogenomics in non-small-cell lung cancer chemotherapy[J].Adv Drug Deliv Rev，2009，61(5)：408-417.
[17]Scagliotti GV，Lodico D，Gozzelino F，et al.Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide[J].Oncology，1985，42(4)：224-228., 百拇医药(罗丽华)